Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Crinetics Pharmaceuticals, Inc is a biotechnology business based in the US. Crinetics Pharmaceuticals shares (CRNX) are listed on the NASDAQ and all prices are listed in US Dollars. Crinetics Pharmaceuticals employs 93 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$17.55|
|52-week range||$11.61 - $21.64|
|50-day moving average||$19.53|
|200-day moving average||$17.08|
|Wall St. target price||$37.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.62|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||-12.25%|
|3 months (2021-04-30)||1.39%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
|Gross profit TTM||$-56,927,000|
|Return on assets TTM||-34.83%|
|Return on equity TTM||-61.53%|
|Market capitalisation||$654.3 million|
TTM: trailing 12 months
There are currently 1.3 million Crinetics Pharmaceuticals shares held short by investors – that's known as Crinetics Pharmaceuticals's "short interest". This figure is 3.8% down from 1.4 million last month.
There are a few different ways that this level of interest in shorting Crinetics Pharmaceuticals shares can be evaluated.
Crinetics Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Crinetics Pharmaceuticals shares currently shorted divided by the average quantity of Crinetics Pharmaceuticals shares traded daily (recently around 245400). Crinetics Pharmaceuticals's SIR currently stands at 5.34. In other words for every 100,000 Crinetics Pharmaceuticals shares traded daily on the market, roughly 5340 shares are currently held short.
However Crinetics Pharmaceuticals's short interest can also be evaluated against the total number of Crinetics Pharmaceuticals shares, or, against the total number of tradable Crinetics Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Crinetics Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Crinetics Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0563% of the tradable shares (for every 100,000 tradable Crinetics Pharmaceuticals shares, roughly 56 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Crinetics Pharmaceuticals.
Find out more about how you can short Crinetics Pharmaceuticals stock.
We're not expecting Crinetics Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Crinetics Pharmaceuticals's shares have ranged in value from as little as $11.61 up to $21.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Crinetics Pharmaceuticals's is 1.2582. This would suggest that Crinetics Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Crinetics Pharmaceuticals, Inc. , a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist to treat congenital hyperinsulinism, which is in phase 1 clinical trial; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase 1 clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California. .
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.